J&J’s Rybrevant/Lazcluze MARIPOSA Update Shows Greater Gains Over Tagrisso
Subcutaneous Rybrevant Data Reinforce Safety, Convenience
Survival and other benefits with J&J’s EGFR/MET inhibitor Rybrevant plus EGFR inhibitor Lazcluze relative to AstraZeneca’s Tagrisso in first-line EGFR-mutant NSCLC continued to improve at 31.1 months.
